chr3-8745688-G-T
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 6P and 4B. PM1PM5PP3_ModerateBS2
The ENST00000343849.3(CAV3):c.277G>T(p.Ala93Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000204 in 1,614,098 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A93T) has been classified as Likely pathogenic.
Frequency
Consequence
ENST00000343849.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CAV3 | NM_033337.3 | c.277G>T | p.Ala93Ser | missense_variant | 2/2 | ENST00000343849.3 | NP_203123.1 | |
CAV3 | NM_001234.5 | c.277G>T | p.Ala93Ser | missense_variant | 2/3 | NP_001225.1 | ||
OXTR | XR_007095681.1 | n.1885-3086C>A | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CAV3 | ENST00000343849.3 | c.277G>T | p.Ala93Ser | missense_variant | 2/2 | 1 | NM_033337.3 | ENSP00000341940 | P1 | |
CAV3 | ENST00000397368.2 | c.277G>T | p.Ala93Ser | missense_variant | 2/3 | 1 | ENSP00000380525 | P1 | ||
CAV3 | ENST00000472766.1 | n.155+11698G>T | intron_variant, non_coding_transcript_variant | 2 |
Frequencies
GnomAD3 genomes AF: 0.000105 AC: 16AN: 152166Hom.: 1 Cov.: 32
GnomAD3 exomes AF: 0.0000199 AC: 5AN: 251184Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135760
GnomAD4 exome AF: 0.0000116 AC: 17AN: 1461814Hom.: 0 Cov.: 32 AF XY: 0.0000110 AC XY: 8AN XY: 727192
GnomAD4 genome AF: 0.000105 AC: 16AN: 152284Hom.: 1 Cov.: 32 AF XY: 0.000121 AC XY: 9AN XY: 74458
ClinVar
Submissions by phenotype
not provided Uncertain:4
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jan 05, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Feb 15, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Oct 31, 2022 | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 19697367, 12666119, 27184587) - |
Uncertain significance, criteria provided, single submitter | clinical testing | AiLife Diagnostics, AiLife Diagnostics | Jan 06, 2022 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 15, 2023 | Variant summary: CAV3 c.277G>T (p.Ala93Ser) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2e-05 in 251184 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.277G>T in individuals affected with Long QT Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. However, another variant at this position, c.277G>A (p.A93T) has been associated with Rippling muscle disease and Long QT syndrome in ClinVar. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Long QT syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 28, 2018 | This sequence change replaces alanine with serine at codon 93 of the CAV3 protein (p.Ala93Ser). The alanine residue is highly conserved and there is a moderate physicochemical difference between alanine and serine. This variant is present in population databases (rs28936686, ExAC 0.05%). This variant has not been reported in the literature in individuals with CAV3-related disease. ClinVar contains an entry for this variant (Variation ID: 180798). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. Variants that disrupt the p.Ala93 amino acid residue in CAV3 have been observed in affected individuals (PMID: 27184587, 12666119, 15668980, 196973670). This suggests that it is a clinically significant residue, and that other variants that disrupt this residue are likely to be causative of disease. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 05, 2024 | The p.A93S variant (also known as c.277G>T), located in coding exon 2 of the CAV3 gene, results from a G to T substitution at nucleotide position 277. The alanine at codon 93 is replaced by serine, an amino acid with similar properties. Another alteration at the same codon, p.A93T (c.277G>A), has been has been reported in the homozygous state in individuals with rippling muscle disease (RMD) and limb-girdle muscular dystrophy, and one study indicated reduction of CAV3 protein expression and caveolae in skeletal muscle from a homozygous individual (Kubisch C et al. Ann. Neurol., 2003 Apr;53:512-20; Kubisch C et al. Ann. Neurol., 2005 Feb;57:303-4; Magri F et al. Muscle Nerve, 2016 May). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at